Nanobiotix: Initial Data on its Anticancer Treatment Revealed
Nanobiotix announces the presentation of the first data from the CONVERGE study, conducted by Johnson & Johnson, on its candidate product JNJ-1900 (NBTXR3) for the treatment of stage III inoperable non-small cell lung cancer. These data were presented at the annual European Lung Cancer Congress (ELCC 2026).
Innovative Mechanism of Action
JNJ-1900 (NBTXR3) consists of functionalized hafnium oxide nanoparticles, administered via a single intratumoral injection and activated by radiotherapy. The mechanism of action of the candidate product is designed to induce the death of tumor cells in the injected tumor when activated by radiotherapy, subsequently triggering an adaptive immune response and long-term anticancer memory. Nanobiotix believes that, due to its physical mechanism of action, JNJ-1900 (NBTXR3) could be suitable for all solid tumors that can be treated with radiotherapy and all therapeutic combinations, particularly checkpoint inhibitors. The candidate product is evaluated in multiple solid tumors alone or in combination.
Strategic Collaborations to Extend Development
Nanobiotix has committed to a strategy of collaboration with world-class partners to extend the development of the candidate product alongside its priority development pathways. In 2019, the company entered into a broad and comprehensive clinical research collaboration with the MD Anderson Cancer Center at the University of Texas to sponsor several studies to evaluate JNJ-1900 (NBTXR3) in various types of tumors and in combinations with different anticancer agents. In 2023, Nanobiotix announced a global licensing agreement for the co-development and commercialization of JNJ-1900 (NBTXR3) with Janssen Pharmaceutica NV, a Johnson & Johnson company.
